MedDataX Logo

Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction

NCT ID: NCT00141349

Last Updated: 2006-07-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-02-28

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Impotence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UK-369,003

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Erectile dysfunction as defined by DSM-IV. Patients should have been PDE5 inhibitor respondents

Exclusion Criteria

* Alpha blockers and Nitrates of any preparation
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Birmingham, Alabama, United States

Site Status

Pfizer Investigational Site

Birmingham, Alabama, United States

Site Status

Pfizer Investigational Site

Birmingham, Alabama, United States

Site Status

Pfizer Investigational Site

Mesa, Arizona, United States

Site Status

Pfizer Investigational Site

Mesa, Arizona, United States

Site Status

Pfizer Investigational Site

Mesa, Arizona, United States

Site Status

Pfizer Investigational Site

Tempe, Arizona, United States

Site Status

Pfizer Investigational Site

Beverly Hills, California, United States

Site Status

Pfizer Investigational Site

San Bernardino, California, United States

Site Status

Pfizer Investigational Site

Torrance, California, United States

Site Status

Pfizer Investigational Site

Waterbury, Connecticut, United States

Site Status

Pfizer Investigational Site

Aventura, Florida, United States

Site Status

Pfizer Investigational Site

Pembroke Pines, Florida, United States

Site Status

Pfizer Investigational Site

St. Petersburg, Florida, United States

Site Status

Pfizer Investigational Site

West Palm Beach, Florida, United States

Site Status

Pfizer Investigational Site

Evansville, Indiana, United States

Site Status

Pfizer Investigational Site

Fort Wayne, Indiana, United States

Site Status

Pfizer Investigational Site

Jeffersonville, Indiana, United States

Site Status

Pfizer Investigational Site

Metairie, Louisiana, United States

Site Status

Pfizer Investigational Site

Metairie, Louisiana, United States

Site Status

Pfizer Investigational Site

Milford, Massachusetts, United States

Site Status

Pfizer Investigational Site

Kansas City, Missouri, United States

Site Status

Pfizer Investigational Site

New Brunswick, New Jersey, United States

Site Status

Pfizer Investigational Site

Albany, New York, United States

Site Status

Pfizer Investigational Site

Endwell, New York, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

Raleigh, North Carolina, United States

Site Status

Pfizer Investigational Site

Raleigh, North Carolina, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Beachwood, Ohio, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Cleveland, Ohio, United States

Site Status

Pfizer Investigational Site

Bryan, Texas, United States

Site Status

Pfizer Investigational Site

Sugar Land, Texas, United States

Site Status

Pfizer Investigational Site

Salt Lake City, Utah, United States

Site Status

Pfizer Investigational Site

West Jordan, Utah, United States

Site Status

Pfizer Investigational Site

Norfolk, Virginia, United States

Site Status

Pfizer Investigational Site

Richmond, Virginia, United States

Site Status

Pfizer Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3711029

Identifier Type: -

Identifier Source: org_study_id